All In Biotech

Drug Trial Radar · NCT00003814

Eflornithine in Treating Patients With Bladder Cancer

Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer

Last checked: Nov 20, 2026Latest source record: Dec 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

450

Planned (sponsor's estimate)

Start

Feb 1999

Primary completion

Not stated

Study completion May 2007

Sponsor

Sponsor type
NIH
First posted
Feb 20, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of eflornithine in treating patients who have newly diagnosed or recurrent bladder cancer.

Conditions

  • Bladder Cancer

Interventions

  • eflornithineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

61 sites in 1 country. Site status is shown where the registry gives one.

  • Urology Associates

    Birmingham, Alabama

  • Intouch Research

    Huntsville, Alabama

  • Advanced Urology Medical Center

    Anaheim, California

  • Citrus Valley Urological Medical Group

    Glendora, California

  • University of California San Diego Cancer Center

    La Jolla, California

  • San Diego Urology Center

    La Mesa, California

  • South Coast Urological Medical Group

    Laguna Hills, California

  • Foothill Urology Associates

    Pasadena, California

  • San Bernadino Urological Associates

    San Bernadino, California

  • DRC and Urological Physicians of San Diego

    San Diego, California

  • UCSF Cancer Center and Cancer Research Institute

    San Francisco, California

  • Urology Specialists, P.C.

    Waterbury, Connecticut

  • George Washington University Hospital

    Washington D.C., District of Columbia

  • Tampa Bay Meical Research

    Clearwater, Florida

  • University of Florida - Gainesville

    Gainesville, Florida

  • Urology Health Center

    New Port Richey, Florida

  • Barzell, Whitmore, Treiman and Dunne - The Urology Treatment Center

    Sarasota, Florida

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Piedmont Urology PC

    Atlanta, Georgia

  • Georgia Urology

    Atlanta, Georgia

  • Urology Associates, Inc.

    Marietta, Georgia

  • University of Chicago Cancer Research Center

    Chicago, Illinois

  • Indiana University Cancer Center

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Wichita Clinic, P.A.

    Wichita, Kansas

  • 206 Research Associates

    Greenbelt, Maryland

  • Mid Atlantic Clinical Research

    Rockville, Maryland

  • Lahey Clinic - Burlington

    Burlington, Massachusetts

  • Fallon Clinic, Inc.

    Worcester, Massachusetts

  • Urology Surgical Associates

    Springfield, Missouri

  • Washington University Barnard Cancer Center

    St Louis, Missouri

  • Office of Sheldon Freedman

    Las Vegas, Nevada

  • Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • University Hospital of New Mexico

    Albuquerque, New Mexico

  • St. Joseph West Mesa Center

    Albuquerque, New Mexico

  • Cancer Center of Albany Medical Center

    Albany, New York

  • Veterans Affairs Medical Center - Albany

    Albany, New York

  • Medical & Clinical Research Associates, LLC

    Bay Shore, New York

  • Mount Sinai Medical Center, NY

    New York, New York

  • University of Rochester Cancer Center

    Rochester, New York

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.